Allogeneic mesenchymal stem cell therapy - GC Biopharma
Alternative Names: Stem cell therapy - GC BiopharmaLatest Information Update: 28 Feb 2025
At a glance
- Originator GC Pharma
- Developer GC Biopharma
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hypoparathyroidism
Highest Development Phases
- No development reported Hypoparathyroidism
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Hypoparathyroidism in South Korea (Parenteral)
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 17 Jan 2022 Allogeneic mesenchymal stem cell therapy - GC Pharma is available for licensing as of 17 Jan 2022. http://www.globalgreencross.com/eng/research/collaboration.do (GC Pharma website, January 2022)